We read with great interest the editorial by Singh1 commenting on the study by Mulqueen et al2 that showed similar rates of monosodium urate crystal dissolution in joints and tendons during treat-to-target (T2T) urate-lowering therapy (ULT). Dr. Singh eloquently articulates the compelling pathophysiological rationale for T2T: complete tophus resolution on dual-energy computed tomography within 12 months represents "an impressive notable finding" that is "uncommon or rare in chronic medical conditions."1
Therán-León et al. (Fri,) studied this question.